The report, "From Stripping to Light," analyzes over a decade of Medicare data and trade flows to confirm that traditional vein-stripping procedures have effectively vanished from clinical practice. In the United States, the share of Medicare venous services attributed to open surgery plummeted from 10.3% in 2013 to just 4.5% by 2024. As clinicians abandon invasive techniques, the USD 1.4–1.6 billion global device market is increasingly defined by a "razor-and-blade" economic model.
Value is now concentrated in high-frequency, single-use consumables—such as specialized fibers, sheaths, and guidewires—rather than the laser consoles themselves. Data from 56 FDA 510(k) clearances since 1997 reveals that 40 filings were for single-use kits, compared to only 11 for capital hardware. While North America remains the dominant region, Asia-Pacific represents the most significant growth opportunity, with a compound annual growth rate reaching 8.4%. Lily Nan, founder of Weihai Medison, noted that this durable shift toward minimally invasive, recurring-revenue procedures is where the company is centering its global strategy, particularly with its NMPA-registered 1470 nm laser fibers.

Comments (0)
No comments yet. Be the first!